Premature ovarian failure: etiology and possible prevention

References

• Hoek A, Schoemaker J, Drexhage HA. Premature ovarian failure and ovarian autoimmunity. Endocr. Rev.18, 107–134 (1997).
   PubMed Web of Science ®Google Scholar
• Skillern A, Rajkovic A. Recent developments in identifying genetic determinants of premature ovarian failure. Sex. Dev.2(4–5), 228–243 (2008).
   Google Scholar
• Simpson JL. Genetic and phenotypic heterogeneity in ovarian failure: overview of selected candidate genes. Ann. NY Acad. Sci.1135, 146–154 (2008).
   PubMed Web of Science ®Google Scholar
• Goswami D, Conway GS. Premature ovarian failure. Hum. Reprod. Update11(4), 391–410 (2005).
   PubMed Web of Science ®Google Scholar
• Krauss CM, Turksoy RN, Atkins L, McLaughin C, Brown L, Page DC. Familial premature ovarian failure due to an interstitial deletion of the long arm of the 3 chromosome. N. Engl. J. Med.317, 125–131 (1987).
   PubMed Web of Science ®Google Scholar
• Chen YT, Mattison DR, Feigenbaum L, Fukui H, Schulman JD. Reduction in oocyte number following prenatal exposure to a diet high in galactose. Science214, 1145–1147 (1981).
   PubMed Web of Science ®Google Scholar
• Forges T, Monnier-Barbarino P, Leheup B, Jouvet P. Pathophysiology of impaired ovarian function in galactosaemia. Hum. Reprod. Update12(5), 573–584 (2006).
   PubMed Web of Science ®Google Scholar
• Blumenfeld Z, von Wolff M. GnRH-analogues and oral contraceptives for fertility preservation in women during chemotherapy. Hum. Reprod. Update14(6), 543–552 (2008).
   PubMed Web of Science ®Google Scholar
• Morrison JC, Givens JR, Wiser WL, Fish SA. Mumps oophoritis: a cause of premature menopause. Fertil. Steril.26, 655–659 (1975).
   PubMed Web of Science ®Google Scholar
• Blumenfeld Z, Halachmi S, Peretz BA et al. Premature ovarian failure – the prognostic application of autoimmunity on conception after ovulation induction. Fertil. Steril.59, 750–755 (1993).
   PubMed Web of Science ®Google Scholar
• van Kasteren YM, Hoek A, Schoemaker J. Ovulation induction in premature ovarian failure: a placebo-controlled randomized trial combining pituitary suppression with gonadotropin stimulation. Fertil. Steril.64, 273–278 (1995).
   PubMed Web of Science ®Google Scholar
• Bath LE, Wallace WH, Critchley HO. Late effects of the treatment of childhood cancer on the female reproductive system and the potential for fertility preservation. Br. J. Obstet. Gynaecol.109, 107–114 (2002).
   Google Scholar
• Sklar CA, Mertens AC, Mitby P et al. Premature menopause in survivors of childhood cancer: a report from the childhood cancer survivor study. J. Natl Cancer Inst.98, 890–896 (2006).
   PubMed Web of Science ®Google Scholar
• Blumenfeld Z. GnRH-agonists in fertility preservation. Curr. Opin. Endocrinol. Diabetes Obes.15, 523–528 (2008).
   PubMedGoogle Scholar
• Matzuk MM, Lamb DJ. Genetic dissection of mammalian fertility pathways. Nat. Cell Biol.4(Suppl.), S41–S49 (2002).
   PubMedGoogle Scholar
• Simpson JL, Rajkovic A. Ovarian differentiation and gonadal failure. Semin. Med. Genet.89, 186–200 (1999).
   Google Scholar
• Meduri G, Touraine P, Beau I et al. Delayed puberty and primary amenorrhea associated with a novel mutation of the human follicle-stimulating hormone receptor: clinical, histological, and molecular studies. J. Clin. Endocrinol. Metab.88, 3491–3498 (2003).
   PubMed Web of Science ®Google Scholar
• Ottolenghi C, Pelosi E, Tran J et al. Loss of Wnt4 and Foxl2 leads to female-to-male sex reversal extending to germ cells. Hum. Mol. Genet.16, 2795–2804 (2007).
   PubMedGoogle Scholar
• Reddy P, Liu L, Adhikari D et al. Oocyte-specific deletion of PTEN causes premature activation of the primordial follicle pool. Science319, 611–613 (2008).
   PubMed Web of Science ®Google Scholar
• Ledig S, Ropke A, Haeusler G, Hinney B, Wieacker P. BMP15 mutations in XX gonadal dysgenesis and premature ovarian failure. Am. J. Obstet. Gynecol.198, 84.e1–84.e5 (2008).
   Google Scholar
• Zhao H, Chen Z, Qin Y et al. Transcription factor FIGLA is mutated in patients with premature ovarian failure. Am. J. Hum. Genet.82, 1342–1348 (2008).
   PubMedGoogle Scholar
• Anderson RA, Fulton N, Cowan G, Coutts S, Saunders PT. Conserved and divergent patterns of expression of DAZL, VASA and OCT4 in the germ cells of the human fetal ovary and testis. BMC Dev. Biol.18, 136 (2007).
   Google Scholar
• Kerr CL, Hill CM, Blumenthal PD, Gearhart JD. Expression of pluripotentic stem cell markers in the human fetal ovary. Hum. Reprod.23, 589–599 (2008).
   Google Scholar
• Pires ES, Meherji PK, Vaidya RR, Parikh FR, Ghosalkar MN, Khole VV. Specific and sensitive immunoassays detect multiple anti-ovarian antibodies in women with infertility. J. Histochem. Cytochem.55, 1181–1190 (2007).
   Google Scholar
• Badawy A, Goda H, Ragab A. Induction of ovulation in idiopathic premature ovarian failure: a randomized double-blind trial. Reprod. Biomed. Online15, 215–219 (2007).
   PubMed Web of Science ®Google Scholar
• Chang SH, Kim CS, Lee KS et al. Premenopausal factors influencing premature ovarian failure and early menopause. Maturitas58(1), 19–30 (2007).
   PubMed Web of Science ®Google Scholar
• Matikainen T, Perez GI, Jurisicova A et al. Aromatic hydrocarbon receptor-driven Bax gene expression is required for premature ovarian failure caused by biohazardous environmental chemicals. Nat. Genet.28(4), 355–360 (2001).
   PubMed Web of Science ®Google Scholar
• Hoyer PB, Devine PJ, Hu X, Thompson KE, Sipes IG. Ovarian toxicity of 4-vinylcyclohexene diepoxide: a mechanistic model. Toxicol. Pathol.29(1), 91–99 (2001).
   PubMed Web of Science ®Google Scholar
• Crain DA, Janssen SJ, Edwards TM et al. Female reproductive disorders: the roles of endocrine-disrupting compounds and developmental timing. Fertil. Steril.90(4), 911–940 (2008).
   PubMed Web of Science ®Google Scholar
• American Cancer Society. Cancer Facts and Figures 2005. American Cancer Society, Atlanta, GA, USA (2005).
   Google Scholar
• Nieman CL, Kazer R, Brannigan RE et al. Cancer survivors and infertility: a review of a new problem and novel answers. J. Support. Oncol.4, 171–178 (2006).
   PubMedGoogle Scholar
• Marhhom E, Cohen I. Fertility preservation options for women with malignancies. Obstet. Gynecol. Surv.62, 58–72 (2007).
   PubMed Web of Science ®Google Scholar
• Beck-Fruchter R, Weiss A, Shalev E. GnRH agonist therapy as ovarian protectants in female patients undergoing chemotherapy: a review of the clinical data. Hum. Reprod. Update14(6), 553–561 (2008).
   PubMed Web of Science ®Google Scholar
• Badawy A, Elnashar A, El-Ashry M, Shahat M. Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study. Fertil. Steril.337(3), 195–206 (2008).
   Google Scholar
• Ataya K, Rao LV, Laurence E, Kimmel R. Luteinizing hormone-releasing agonist inhibits cyclophosphamide induced ovarian follicular depletion in Rhesus monkeys. Biol. Reprod.52, 365–372 (1995).
   PubMed Web of Science ®Google Scholar
• Imai A, Sugiyama M, Furui T, Tamaya T, Ohno T. Direct protection by a gonadotropin-releasing hormone analog from doxorubicin-induced granulosa cell. damage. Gynecol. Obstet. Invest.63, 102–106 (2007).
   PubMed Web of Science ®Google Scholar
• Edgar AB, Wallace WHB. Pregnancy in women who had cancer in childhood. Eur. J. Cancer43, 1890–1894 (2007).
   PubMed Web of Science ®Google Scholar
• Sklar CA, Mertens AC, Mitby P et al. Premature menopause in survivors of childhood cancer: a report from the childhood cancer survivor study. J. Natl Cancer Inst.98, 890–896 (2006).
   PubMed Web of Science ®Google Scholar
• Blumenfeld Z, Avivi I, Eckman A et al. Gonadotropin releasing hormone agonist decreases chemotherapy induced gonadotoxicity and premature ovarian failure in young female patients with Hodgkin lymphoma. Fertil. Steril.89, 166–173 (2008).
   PubMed Web of Science ®Google Scholar
• Blumenfeld Z. How to preserve fertility in young women exposed to chemotherapy? The role of GnRH agonist cotreatment in addition to cryopreservation of embrya, oocytes, or ovaries. Oncologist12, 1044–1054 (2007).
   PubMed Web of Science ®Google Scholar
• Moore HCF. Ovarian failure after chemotherapy for breast cancer and the role of gonadotropin-releasing hormone analogs in protection of ovarian function. In: ASCO 2008 Educational Book – 44th Annual Meeting May 30–June 3 2008, Chicago, IL. Govindan R, Curzio J (Eds). American Society of Clinical Oncology, Alexandria, VA, USA 39–42 (2008).
   Google Scholar
• Recchia F, Saggio G, Amiconi G et al. Gonadotropin-releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinoma. Cancer106, 514–523 (2006).
   PubMed Web of Science ®Google Scholar
• Del Mastro L, Catzeddu T, Boni L et al. Prevention of chemotherapy-induced menopause by temporary ovarian suppression with goserelin in young early breast cancer patients. Ann. Oncol.17, 74–78 (2006).
   PubMed Web of Science ®Google Scholar
• Cuzick J, Ambroisine L, Davidson N et al. LHRH-Agonists in Early Breast Cancer Overview group. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet369, 1711–1723 (2007).
   PubMed Web of Science ®Google Scholar
• Sharma R, Hamilton A, Beith J. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women. Cochrane Database Syst. Rev.4, CD004562 (2008).
   Google Scholar
• Knight PG, Glister C. TGF-β superfamily members and ovarian follicle development. Reproduction132, 191–206 (2006).
   PubMed Web of Science ®Google Scholar
• Blumenfeld Z, Benaroush M, Zuckerman T. Spontaneous pregnancy and normal delivery after repeated autologous bone marrow transplantation and GnRH agonist treatment. Hum. Reprod.22, 2346 (2007).
   Google Scholar